PHIBRO ANIMAL HEALTH CORP
No SEC Form 4 filings for $PAHC in the last 30 days.
See all $PAHC insider activity →Corcept (CORT) reported the highest Q2 earnings beat and guidance raise, with its stock up 17.2%. Zoetis (ZTS) missed expectations, with flat revenue and lower guidance, but its stock rose 10.8%. Bristol-Myers Squibb (BMY) beat estimates with 5.7% revenue growth, while Phibro Animal Health (PAHC) reported a 4.8% revenue increase and a 10.3% stock rise.
Phibro Animal Health (PAHC) issued 2027 guidance, projecting net sales of $1.55b-$1.60b and net income of $122m-$132m. The company reported 2026 sales of $1.518b and net income of $99.72m. Analysts' price targets range from $38 to $58, with a consensus of $45.60, suggesting a 16.1% undervaluation. The stock has seen a 90-day return of 17.95% and a 3-year return above 200%.
Phibro Animal Health (PAHC) reported fiscal 2026 net sales of $1.5B, adjusted EBITDA up 39% to $255M, and EPS up 48% to $3.22. The growth was driven by a recent acquisition and organic growth across segments. Guidance for fiscal 2027 expects slower growth with net sales of $1.55B-$1.6B and EBITDA of $258M-$268M. Free cash flow was $9.9M due to inventory buildup, with debt at $737.9M and a leverage ratio of 2.9x EBITDA.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning PAHC (PHIBRO ANIMAL HEALTH CORP). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent PAHC coverage spans earnings, corporate actions and financial news.
Recap of already‑published earnings.
The new guidance raises expectations for revenue and profit growth in FY2027.
Strong earnings beat and modest guidance may support short‑term upside, but rising debt and slowing growth raise downside risk.
Strong earnings and upbeat guidance suggest upside potential, especially if regulatory outcome in Brazil is favorable.
Guidance suggests modest top‑line growth and stable margins, but Brazil regulatory uncertainty may weigh on near‑term sentiment.
AlphAI scores every news story that mentions PAHC with an AI model for sentiment and relevance, and aggregates insider trades from PHIBRO ANIMAL HEALTH CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
Corcept (CORT) reported the highest Q2 earnings beat and guidance raise, with its stock up 17.2%. Zoetis (ZTS) missed expectations, with flat revenue and lower guidance, but its stock rose 10.8%. Bristol-Myers Squibb (BMY) beat estimates with 5.7% revenue growth, while Phibro Animal Health (PAHC) reported a 4.8% revenue increase and a 10.3% stock rise.
2 min readPhibro Animal Health (PAHC) issued 2027 guidance, projecting net sales of $1.55b-$1.60b and net income of $122m-$132m. The company reported 2026 sales of $1.518b and net income of $99.72m. Analysts' price targets range from $38 to $58, with a consensus of $45.60, suggesting a 16.1% undervaluation. The stock has seen a 90-day return of 17.95% and a 3-year return above 200%.
3 min readPhibro Animal Health (PAHC) reported fiscal 2026 net sales of $1.5B, adjusted EBITDA up 39% to $255M, and EPS up 48% to $3.22. The growth was driven by a recent acquisition and organic growth across segments. Guidance for fiscal 2027 expects slower growth with net sales of $1.55B-$1.6B and EBITDA of $258M-$268M. Free cash flow was $9.9M due to inventory buildup, with debt at $737.9M and a leverage ratio of 2.9x EBITDA.
3 min readPhibro (PAHC) reported Q4 2026 net sales of $396.7M, up 5%, and adjusted EBITDA of $255M, up 39% YoY. Full-year sales reached $1.518B, up 17%, with adjusted EBITDA up 39%. CEO Dani Bendheim highlighted strong performance across segments, including a 20% increase in Mineral Nutrition sales. The company provided fiscal 2027 guidance, expecting net sales of $1.55B-$1.6B and adjusted EBITDA of $258M-$268M. Phibro also announced the closure of a Chicago facility and discussed regulatory uncertainties
2 min readPhibro Animal Health (PAHC) reported Q4 and full-year 2026 results, with legacy MFA and other revenue up 4%, Nutritional Specialties up 9%, and vaccine revenue up 14%. The company expects fiscal 2027 sales of $1.55B-$1.60B and adjusted EBITDA of $258M-$268M, with growth driven by acquired MFA products and international demand. However, Brazil regulatory uncertainty and higher input costs may impact performance. Phibro also plans to close its Chicago Heights facility, expecting $15M-$20M in annua
2 min readPhibro Animal Health (PAHC) reported Q2 CY2026 revenue of $396.7M, up 4.8% YoY, exceeding estimates. Full-year guidance was raised 1.9% above consensus. Non-GAAP EPS of $0.85 beat estimates by 17.1%. The stock rose 7.3% post-earnings.
2 min readPHIBRO ANIMAL HEALTH CORP (PAHC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 For Immediate Release Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance TEANECK, N.J., August 26, 2026 (Business Wire) – Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) tod
3 min readPhibro Animal Health (PAHC) will report Q4'26 earnings on August 26, with revenue expected at $381.18M and EPS at $0.71, according to estimates.
1 min readPHIBRO ANIMAL HEALTH CORP (PAHC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001069899 0001069899 2026-06-25 2026-06-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report
4 min readPhibro Animal Health (NASDAQ:PAHC) shares rose 10.2% in the afternoon after director E. Thomas Corcoran bought $317,700 of stock on May 29: 10,000 shares at a weighted average $31.77. His holdings increased to 41,459 shares, according to the report. The stock is down 15.7% YTD at $31.43.
4 min read
